Jubilant Biosys and Orion entered a collaboration to discover small molecule inhibitors in the neuroscience therapeutic area. The research deal is aimed at developing a drug for pain management.
As part of the agreement, Orion will utilize Jubilant’s experience in drug discovery and preclinical development to address pain management needs. Jubilant will offer integrated drug discovery services across early discovery, synthetic, and medicinal chemistry including scale up and preclinical services. The research for the project, which has been initiated, will be undertaken primarily at R&D labs of Jubilant Biosys in India and partially at Jubilant Discovery Center in the U.S.
Jubilant will receive research funding from Orion for delivering hit, lead generation, and optimization milestone in accordance to a predefined research plan. Under the alliance, Orion will provide royalty to Jubilant and will retain ownership of the compounds developed under the collaboration with exclusive worldwide rights.
